

Shinya Rai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062503/publications.pdf>

Version: 2024-02-01

38
papers

969
citations

933447

10
h-index

477307

29
g-index

42
all docs

42
docs citations

42
times ranked

1198
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363. | 27.0 | 278 |
| 2 | C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. <i>International Journal of Hematology</i> , 2022, 115, 310. | 1.6 | 1 |
| 3 | CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. <i>International Journal of Hematology</i> , 2022, 115, 336-349. | 1.6 | 1 |
| 4 | Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. <i>Cancer Science</i> , 2022, 113, 2085-2096. | 3.9 | 15 |
| 5 | Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells. <i>British Journal of Haematology</i> , 2022, 198, 360-372. | 2.5 | 1 |
| 6 | Asia subpopulation analysis from the phase III POLARIX trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 7558-7558. | 1.6 | 0 |
| 7 | Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 507-509. | 1.3 | 0 |
| 8 | Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. <i>International Journal of Hematology</i> , 2021, 114, 205-216. | 1.6 | 3 |
| 9 | Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus. <i>Life</i> , 2021, 11, 463. | 2.4 | 1 |
| 10 | A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 2845-2854. | 3.9 | 24 |
| 11 | Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. <i>Cancer Science</i> , 2021, 112, 3627-3635. | 3.9 | 32 |
| 12 | Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation. <i>Leukemia Research Reports</i> , 2021, 15, 100256. | 0.4 | 0 |
| 13 | Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 303-303. | 1.4 | 4 |
| 14 | Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma. <i>Blood</i> , 2021, 138, 1345-1345. | 1.4 | 1 |
| 15 | Decreased expression of cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. <i>Cancer Science</i> , 2021, , . | 3.9 | 5 |
| 16 | Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases. <i>Blood</i> , 2021, 138, 4523-4523. | 1.4 | 0 |
| 17 | Two-Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia and Two-Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2021, 138, 1352-1352. | 1.4 | 2 |
| 18 | The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, LBA-1-LBA-1. | 1.4 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome. <i>Annals of Hematology</i> , 2020, 99, 381-383. | 1.8 | 1 |
| 20 | Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2020, 14, 100219. | 0.4 | 6 |
| 21 | A multicenter, open-label, phase II study of tirabrutinib (ONO/GS4059) in patients with Waldenström's macroglobulinemia. <i>Cancer Science</i> , 2020, 111, 3327-3337. | 3.9 | 60 |
| 22 | Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. <i>Nature Communications</i> , 2020, 11, 4147. | 12.8 | 15 |
| 23 | Tumour immune microenvironment in duodenal-type follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 243-252. | 2.5 | 5 |
| 24 | Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy. <i>Viruses</i> , 2020, 12, 416. | 3.3 | 4 |
| 25 | The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia. <i>Internal Medicine</i> , 2020, 59, 2745-2749. | 0.7 | 3 |
| 26 | Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity. <i>Blood</i> , 2020, 136, 14-15. | 1.4 | 0 |
| 27 | Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells. <i>Cells</i> , 2019, 8, 226. | 4.1 | 25 |
| 28 | Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295. | 1.6 | 388 |
| 29 | Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. <i>British Journal of Haematology</i> , 2019, 184, 122-122. | 2.5 | 1 |
| 30 | Antidiuretic hormone and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. <i>British Journal of Haematology</i> , 2019, 184, 121-121. | 2.5 | 1 |
| 31 | Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality. <i>Frontiers in Immunology</i> , 2018, 9, 3031. | 4.8 | 5 |
| 32 | VII. Pathological Mechanism and Treatment of Therapy-related AML. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1316-1323. | 0.0 | 0 |
| 33 | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. <i>Cancers</i> , 2018, 10, . | 3.7 | 0 |
| 34 | Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. <i>Cancers</i> , 2018, 10, 304. | 3.7 | 2 |
| 35 | Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. <i>International Journal of Hematology</i> , 2017, 106, 691-703. | 1.6 | 19 |
| 36 | Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells. <i>PLoS ONE</i> , 2014, 9, e109441. | 2.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Young Patient with Richter Syndrome Presenting with Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma with Different Cell Origins. <i>Internal Medicine</i> , 2013, 52, 273-276. | 0.7 | 1 |
| 38 | The Clathrin Assembly Protein PICALM Is Required for Erythroid Maturation and Transferrin Internalization in Mice. <i>PLoS ONE</i> , 2012, 7, e31854. | 2.5 | 47 |